Related Experiment Video
Updated: Jan 29, 2026
07:00
Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
Published on: August 11, 2017
8.6K
Pharmaceutical Approval Update
P & T : a Peer-Reviewed Journal for Formulary Management
|February 16, 2019
Abstract:
Arikayce (amikacin liposome inhalation suspension) for Mycobacterium avium complex lung disease; Xofluza (baloxavir marboxil) for acute uncomplicated influenza; and Nuzyra (omadacycline) for community-acquired bacterial pneumonia and/or acute bacterial skin and skin structure infections.
Insights
New treatments for lung infections, influenza, and bacterial pneumonia are reviewed. These include amikacin liposome inhalation suspension, baloxavir marboxil, and omadacycline for specific bacterial and viral infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Respiratory Medicine
Background:
- Rising incidence of antibiotic-resistant bacteria and viral infections necessitates novel therapeutic strategies.
- Mycobacterium avium complex (MAC) lung disease, influenza, and community-acquired bacterial pneumonia (CABP) pose significant public health challenges.
- Existing treatments may have limitations in efficacy, safety, or resistance development.
Purpose of the Study:
- To review the clinical applications and efficacy of three recently approved or investigated medications.
- To provide an overview of Arikayce (amikacin liposome inhalation suspension), Xofluza (baloxavir marboxil), and Nuzyra (omadacycline).
- To highlight their roles in treating specific infectious diseases.
Main Methods:
- Literature review of clinical trials and post-marketing data.
- Analysis of pharmacokinetic and pharmacodynamic properties.
- Evaluation of safety and tolerability profiles.
Main Results:
- Arikayce demonstrated efficacy in patients with MAC lung disease, particularly in those with limited treatment options.
- Xofluza showed effectiveness in reducing influenza symptom duration and viral shedding.
- Nuzyra provided a novel treatment option for CABP and acute bacterial skin and skin structure infections (ABSSSI).
Conclusions:
- These agents represent important advancements in managing challenging infectious diseases.
- Optimized use of these medications can improve patient outcomes and address unmet needs.
- Continued research and surveillance are crucial for monitoring resistance and long-term effectiveness.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
257
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
257
01:26Pharmaceutical Equivalents
201
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
201
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
192
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
192
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
499
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
499
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
182
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
182
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
161
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
161